Korean FDA approves BASF Pharma Callanish production

Published: 11-Mar-2013

To sell concentrated omega-3 fatty acids in Korea


The Korean Food and Drug Administration (KFDA) has approved BASF Pharma Callanish, a cGMP-certified production facility on the Isle of Lewis, Scotland, to sell concentrated omega-3 fatty acids as active pharmaceutical ingredients in Korea.

BASF Pharma Callanish, formerly Equateq, specialises in the production of highly concentrated omega oils for use in pharmaceuticals and high-end dietary supplements.

‘We are very pleased about this approval since Korea is an important pharmaceutical market for us,’ said Alan Poon, BASF’s Head of Pharma Ingredients & Services in Asia Pacific. ‘We expect approvals in other Asian markets to follow, as we broaden our offering of omega-3 concentrates for the pharmaceutical sector even further.’

You may also like